Stephen Harrison

, United States


Presentations

Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444) 12 April 2019 17:30 - 17:45
Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy 13 April 2019 09:00 - 17:00
The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD 13 April 2019 09:00 - 17:00
Predicting the severity of hepatic steatosis and fibrosis by transient elastography and MRI-based techniques in adults patients with suspected NAFLD 13 April 2019 09:00 - 17:00
MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study 13 April 2019 09:00 - 17:00
MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study 11 April 2019 12:00 - 13:00

Abstracts

MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study NAFLD: Therapy More
The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD NAFLD: Diagnostics and non-invasive assessment More
Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy NAFLD: Diagnostics and non-invasive assessment More
Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444) NAFLD: Therapy More
Predicting the severity of hepatic steatosis and fibrosis by Transient Elastography and MRI-based techniques in adults patients with suspected NAFLD NAFLD: Diagnostics and non-invasive assessment More